Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as JNJ-61178104 Intravenous
JNJ-61178104 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Dose 1: JNJ-61178104 OR Placebo IV | EXPERIMENTAL | Participants will receive either JNJ-61178104 0.1 milligram/kilogram (mg/kg) or Placebo Intravenously (IV) on Day 1. |
| Dose 2: JNJ-61178104 OR Placebo IV | EXPERIMENTAL | Participants will receive either JNJ-61178104 0.3 mg/kg or Placebo IV on Day 1. |
| Dose 3: JNJ-61178104 OR Placebo IV | EXPERIMENTAL | Participants will receive either JNJ-61178104 1 mg/kg or Placebo IV on Day 1. |
| Dose 4: JNJ-61178104 OR Placebo IV | EXPERIMENTAL | Participants will receive either JNJ-61178104 3 mg/kg or Placebo IV on Day 1. |
| Dose 5: JNJ-61178104 OR Placebo IV | EXPERIMENTAL | Participants will receive either JNJ-61178104 10 mg/kg or Placebo IV on Day 1. |
| Dose 6: JNJ-61178104 OR Placebo SC | EXPERIMENTAL | Participants will receive either JNJ-61178104 1 mg/kg or Placebo Subcutaneously (SC) on Day 1. |
| Name | Type | Description |
|---|---|---|
| JNJ-61178104 Intravenous | DRUG | Participants will receive JNJ-61178104 Intravenously on Day 1. |
| JNJ-61178104 Subcutaneous | DRUG | Participants will receive JNJ-61178104 Subcutaneously on Day 1. |
| Placebo | DRUG | Participants will receive placebo on Day 1. |
Inclusion Criteria * Participant must sign an informed consent form (ICF) indicating that he or she understands the purpose of and procedures required for the study and are willing to participate in the study * Participant must have a body weight in the range of 50 Kilogram (kg) to 100 kg, inclusiv...
JNJ-61178104 is an investigational small molecule developed by Johnson & Johnson. It has been studied in a Phase 1 clinical trial in healthy adult participants. No approved indication has been disclosed for this asset, and it remains in clinical development rather than on the market.
JNJ-61178104 is developed by Johnson & Johnson, which trades on the New York Stock Exchange under the ticker JNJ. The company sponsored the Phase 1 study of the compound in healthy volunteers. No partner or licensee for the program has been disclosed.
JNJ-61178104 is in Phase 1 development. One Phase 1 trial has been completed, and no active trials are currently listed for the compound. It is an investigational agent and has not been approved for any indication.
JNJ-61178104 has been evaluated in one clinical trial, NCT02758392, titled A Study to Evaluate Safety and Tolerability of JNJ-61178104 in Healthy Participants. That Phase 1 study is completed, enrolled 54 participants, was randomized, double blind, and controlled, and was conducted in Belgium.
Yes. JNJ-61178104 Intravenous is another name used for JNJ-61178104, so searches for either term refer to the same investigational compound from Johnson & Johnson. The intravenous form is the version studied in the completed Phase 1 trial in healthy participants.
The Phase 1 trial NCT02758392 evaluated the safety and tolerability of JNJ-61178104 in healthy participants. It enrolled 54 adults aged 18 years and older of any sex, used a randomized, double blind, controlled design, and was conducted in Belgium. The study is completed.